Mitochondrial Dynamics Pathway: Fusion and Fission in Neurodegeneration
Overview
Mitochondrial dynamics refers to the continuous processes of fusion and fission that maintain mitochondrial morphology, distribution, and quality control within cells. These opposing processes are essential for mitochondrial health, ATP production, calcium homeostasis, and apoptotic regulation[@chan2020]. In neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD), dysregulation of mitochondrial dynamics represents a central pathogenic mechanism contributing to neuronal dysfunction and death[@chen2023].
The balance between fusion and fission determines mitochondrial morphology—from elongated, interconnected networks to fragmented discrete organelles. This dynamics continuum is governed by a family of dynamin-related proteins (DRPs) that mediate membrane remodeling events on mitochondrial membranes[@giacomello2023]. Understanding how these processes go awry in neurodegeneration provides critical insights into disease mechanisms and therapeutic targeting.
Molecular Machinery of Mitochondrial Dynamics
Fusion Machinery
Mitochondrial fusion is mediated by three large GTPases located on the outer and inner mitochondrial membranes. These dynamin-related proteins orchestrate the sequential fusion of both membranes to form a continuous mitochondrial network[@liu2022].
Mitofusins (MFN1 and MFN2)
...Mitochondrial Dynamics Pathway: Fusion and Fission in Neurodegeneration
Overview
Mitochondrial dynamics refers to the continuous processes of fusion and fission that maintain mitochondrial morphology, distribution, and quality control within cells. These opposing processes are essential for mitochondrial health, ATP production, calcium homeostasis, and apoptotic regulation[@chan2020]. In neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD), dysregulation of mitochondrial dynamics represents a central pathogenic mechanism contributing to neuronal dysfunction and death[@chen2023].
The balance between fusion and fission determines mitochondrial morphology—from elongated, interconnected networks to fragmented discrete organelles. This dynamics continuum is governed by a family of dynamin-related proteins (DRPs) that mediate membrane remodeling events on mitochondrial membranes[@giacomello2023]. Understanding how these processes go awry in neurodegeneration provides critical insights into disease mechanisms and therapeutic targeting.
Molecular Machinery of Mitochondrial Dynamics
Fusion Machinery
Mitochondrial fusion is mediated by three large GTPases located on the outer and inner mitochondrial membranes. These dynamin-related proteins orchestrate the sequential fusion of both membranes to form a continuous mitochondrial network[@liu2022].
Mitofusins (MFN1 and MFN2)
Mitofusin-1 (MFN1) and Mitofusin-2 (MFN2) are dynamin-related GTPases located on the outer mitochondrial membrane. They mediate outer membrane fusion through their GTPase activity and form homotypic and heterotypic complexes:
- MFN1: Primary mediator of outer membrane tethering and fusion, with higher fusion efficiency than MFN2 alone[@chen2007]
- MFN2: Functions in fusion and ER-mitochondria contact sites, also involved in mitochondrial quality control. Mutations cause Charcot-Marie-Tooth neuropathy type 2A[@zuchner2004]
Both proteins contain an N-terminal GTPase domain, middle domain for dimerization, C-terminal transmembrane regions, and HR1 and HR2 heptad repeat domains.
OPA1 (Optic Atrophy 1)
OPA1 is a dynamin-related GTPase located on the inner mitochondrial membrane that mediates inner membrane fusion. It is essential for cristae maintenance, mtDNA stability, and apoptotic resistance[@liao2021]:
- Multiple isoforms generated by alternative splicing
- Proteolytic processing produces long and short forms—long forms mediate fusion while short forms maintain cristae
- Mutations cause autosomal dominant optic atrophy (ADOA)
Fission Machinery
Mitochondrial fission is mediated by DRP1 (Dynamin-related protein 1), which is recruited from the cytosol to mitochondria by outer membrane receptors[@song2022].
DRP1 (Dynamin-related protein 1)
DRP1 is a cytosolic GTPase that assembles into ring-like structures around mitochondria to mediate fission:
- Recruited to mitochondria by outer membrane receptors: FIS1, MFF, and MiD49/50
- GTP hydrolysis drives conformational changes that constrict the mitochondrial membrane
- Post-translational modifications (phosphorylation, ubiquitination, sumoylation) regulate DRP1 activity and recruitment
Fission Receptors| Receptor | Function | Tissue Expression |
|----------|----------|-------------------|
| FIS1 | Adapter protein, recruits DRP1 | Ubiquitous |
| MFF | Major DRP1 receptor | High in brain |
| MiD49/50 | DRP1 recruitment | Neuron-enriched |
The Fusion-Fission Balance
The complete mitochondrial dynamics cycle involves:
Tethering: MFN proteins mediate initial mitochondrial approach
Outer membrane fusion: GTP hydrolysis drives membrane merging
Inner membrane fusion: OPA1 catalyzes inner membrane fusion
Content mixing: Matrix proteins and mtDNA intermix
Network stabilization: Fused mitochondria integrate into the network
Fission initiation: DRP1 recruitment to marked mitochondria
Division: Constriction and separation into daughter mitochondria
Quality control: Damaged components isolated for mitophagyRegulation of Mitochondrial Dynamics
Post-Translational Modifications
Mitochondrial dynamics proteins are extensively regulated by post-translational modifications that respond to cellular signaling and stress conditions[@peng2023]:
| Modification | Enzyme | Target | Effect |
|--------------|--------|--------|--------|
| Phosphorylation (Ser616) | PKA | DRP1 | Inhibits fission |
| Phosphorylation (Ser637) | PKA | DRP1 | Inhibits fission |
| Phosphorylation (Ser600) | CDK1 | DRP1 | Promotes fission |
| Phosphorylation (Ser27) | PKA | MFN1/2 | Inhibits fusion |
| Dephosphorylation | PP1 | MFN1/2 | Restores fusion |
| Ubiquitination | Parkin | MFN1/2 | Targets for degradation |
| Sumoylation | SENP5 | OPA1 | Stabilizes fusion proteins |
| O-GlcNAcylation | OGT | MFN2 | Protects against stress |
Calcium flux regulates dynamics through:
- Calmodulin binding to MFN2[@calcium2019]
- Calcium-dependent activation of OPA1
- Mitochondrial calcium uniporter (MCU) regulation
- Calcineurin-mediated DRP1 dephosphorylation
Energetic Status
ATP and AMP levels influence fusion-fission balance:
- Low ATP inhibits GTP hydrolysis required for fusion
- High energy states promote fusion
- AMPK activation enhances fusion and inhibits fission[@wang2019]
- mTORC1 signaling affects mitochondrial dynamics through transcriptional regulation
Mitochondrial Dynamics in Alzheimer's Disease
Alzheimer's disease features prominent mitochondrial dysfunction, with impaired fusion representing an early event in disease pathogenesis[@wang2022]. Multiple mechanisms contribute to dynamics deficits in AD.
Amyloid-Beta Effects
Amyloid-beta (Aβ) directly interacts with mitochondrial proteins:
- Aβ accumulates within mitochondria in AD brain[@manczak2016]
- Aβ binds to MFN2, reducing fusion efficiency
- Aβ impairs MFN1/2 GTPase activity
- Intramitochondrial Aβ disrupts calcium handling
- Aβ promotes DRP1 recruitment and fission
Tau Pathology Effects
Tau pathology disrupts mitochondrial dynamics:
- Hyperphosphorylated tau impairs mitochondrial transport[@kopeidou2022]
- Tau mediates MFN2 degradation
- Tau interacts with DRP1 to promote fission
- Mitochondrial distribution becomes abnormal in neurons
- Dynamics deficits exacerbate energy failure
Evidence from AD Models
Studies in AD models demonstrate:
- Reduced MFN1/2 expression in AD brain[@wang2019a]
- Increased DRP1 activity and mitochondrial fragmentation
- Fragmented mitochondria in neurons
- Impaired mitochondrial network connectivity
- Correlation between dynamics defects and cognitive decline
Therapeutic Implications
Strategies targeting dynamics in AD include:
- MFN1/2 overexpression approaches[@yang2023]
- Small molecule fusion enhancers
- OPA1 stabilizers
- DRP1 inhibitors
- Combination with mitophagy inducers
Mitochondrial Dynamics in Parkinson's Disease
Parkinson's disease involves prominent mitochondrial dysfunction, particularly in dopaminergic neurons of the substantia nigra pars compacta[@park2023]. The PINK1/Parkin pathway regulates mitochondrial quality control, but fusion and fission also play critical roles.
PINK1/Parkin Pathway
The PINK1/Parkin pathway regulates dynamics:
- PINK1 accumulates on damaged mitochondria[@narendra2008]
- Parkin recruitment leads to ubiquitination of MFN1/2
- PINK1 phosphorylates MFN2 for ubiquitination
- Fusion proteins degraded in quality control
- Fission proteins likewise targeted
Alpha-Synuclein Effects
α-Synuclein aggregation impacts dynamics:
- α-Synuclein localizes to mitochondria[@poehler2014]
- Oligomeric α-Syn disrupts membrane potential
- Fusion efficiency reduced in PD models
- Promotes excessive fission
- Dopaminergic neurons particularly vulnerable
LRRK2 Mutations
LRRK2 (leucine-rich repeat kinase 2) mutations linked to PD:
- G2019S kinase domain mutation most common[@rideout2016]
- Alters mitochondrial dynamics through phosphorylation
- Affects fusion protein phosphorylation status
- Therapeutic targeting of LRRK2 in clinical development
Evidence from PD Models
- Reduced MFN2 in PD brain[@xie2019]
- Fragmented mitochondria in dopaminergic neurons
- Increased DRP1 mitochondrial recruitment
- Mitochondrial motility deficits
- Dynamics defects precede neuron loss
Mitochondrial Dynamics in Amyotrophic Lateral Sclerosis
ALS features mitochondrial dysfunction in motor neurons, with dynamics defects contributing to disease pathogenesis[@shi2020]. Multiple ALS-causing genes affect mitochondrial dynamics.
SOD1 Mutations
Superoxide dismutase 1 (SOD1) mutations:
- Mitochondrial recruitment of mutant SOD1[@liu2020]
- Impaired mitochondrial respiration
- Disrupted fusion machinery
- Axonal mitochondrial fragmentation
C9orf72 Hexanucleotide Expansions
C9orf72 repeat expansions:
- Impaired autophagy of mitochondria[@lopezgonzalez2019]
- Reduced mitochondrial network connectivity
- Fusion deficits in motor neurons
- Nucleocytoplasmic transport defects affect fusion protein expression
TDP-43 Pathology
TDP-43 aggregates in ALS:
- TDP-43 disrupts mitochondrial transport[@wang2018]
- Alters fusion protein expression
- Impaired mitochondrial dynamics
- Contributes to motor neuron degeneration
FUS Mutations
FUS (fused in sarcoma) mutations:
- Mitochondrial dysfunction in models[@deng2015]
- Altered mitochondrial localization
- Fusion deficits in motor neurons
Mitochondrial Dynamics in Huntington's Disease
Huntington's disease involves prominent mitochondrial deficits, with mutant huntingtin directly affecting dynamics machinery[@costa2020].
Mutant Huntingtin Effects
Mutant huntingtin (mHtt) impacts dynamics:
- mHtt binds to MFN2[@shirendeb2009]
- Reduces MFN2 protein levels
- Impairs OPA1 processing
- Promotes excessive fission
- Disrupts mitochondrial network
Bioenergetic Failure
Dynamics defects contribute to:
- Reduced ATP production[@quintanilla2013]
- Impaired calcium buffering
- Increased reactive oxygen species
- Neuronal vulnerability in striatal neurons
Evidence from HD Models
- Reduced MFN1/2 and OPA1 in HD models
- Fragmented mitochondria in striatal neurons
- Correlation with CAG repeat length
- Therapeutic targeting shows promise
Mitochondrial Dynamics in Other Neurodegenerative Conditions
Frontotemporal Dementia
FTD shares mechanistic overlaps with ALS:
- TDP-43 pathology affects dynamics[@rascovsky2019]
- CHMP2B mutations impact mitochondrial function
- Fused in sarcoma (FUS) involvement
Multiple System Atrophy
MSA features:
- Oligodendroglial α-synuclein pathology
- Mitochondrial dysfunction in neurons[@stefanova2019]
- Impaired dynamics in affected brain regions
Progressive Supranuclear Palsy
PSP involves:
- Tau pathology impacts mitochondrial transport
- Brainstem neuron vulnerability[^32]
- Dynamics deficits in subcortical structures
Assessment Methods
Imaging Techniques
Live-cell microscopy
- Real-time visualization of mitochondrial morphology
- Time-lapse imaging of fusion/fission events
- Network connectivity analysis
- Quantitative morphology parameters
Super-resolution microscopy
- STED imaging of mitochondrial structure
- PALM/STORM of dynamics proteins
- High-resolution network analysis
Mitochondrial matrix-targeted reporters
- GFP-based dynamics tracking
- MitoTimer for turnover measurement
- mtDNA distribution analysis
Biochemical Markers
| Marker | Measurement | Significance |
|--------|-------------|--------------|
| OPA1 processing | Western blot | Long vs short isoforms |
| MFN1/2 levels | Immunoblot | Protein expression |
| DRP1 recruitment | Cell fractionation | Fission activity |
| Phosphorylation status | Phospho-specific antibodies | Activity state |
| GTPase activity | GTP hydrolysis assay | Functional status |
Functional Assays
- mtDNA mixing assays: Measure fusion rates
- Oxygen consumption rate (OCR): Mitochondrial function
- Membrane potential analysis: TMRE/JC-1 staining
- ATP production: Luciferase assays
- Calcium handling: Fura-2 imaging
Therapeutic Approaches
Small Molecule Modulators
| Compound | Target | Mechanism | Stage |
|----------|--------|-----------|-------|
| Mdivi-1 | DRP1 | Inhibit fission | Phase I/II |
| Mitochondrial fusion enhancers | MFN1/2 | Promote GTPase activity | Preclinical |
| OPA1 stabilizers | OPA1 | Prevent proteolysis | Research |
| P110 | DRP1 | Selective inhibition | Preclinical |
Gene Therapy Approaches
- AAV-mediated MFN1/2 delivery[@zhang2023]
- OPA1 gene therapy
- CRISPR editing of dynamics genes
- RNA targeting of DRP1
Combination Strategies
Optimal therapeutic approaches may combine:
- Dynamics modulation with mitophagy induction
- Mitochondrial dynamics modulators with metabolic enhancers
- Targeting fusion/fission with antioxidant therapies
- Synergistic effects on neuronal survival
Research Gaps and Future Directions
Current Knowledge Gaps
Temporal dynamics: How fusion/fission defects evolve during disease progression
Cell-type specificity: Why certain neurons are more vulnerable to dynamics deficits
Therapeutic delivery: Targeting dynamics modulators to neurons in vivo
Combination approaches: Optimal sequencing with other mitochondrial therapies
Biomarker development: Non-invasive monitoring of dynamics statusEmerging Research Areas
- Single-cell analysis: Mitochondrial dynamics in specific neuronal populations
- iPSC models: Patient-derived neurons with dynamics mutations
- In vivo imaging: Longitudinal monitoring of mitochondrial networks
- Optogenetic tools: Light-controlled dynamics proteins
- Synthetic biology: Engineered dynamics machinery
Mermaid Pathway Diagram
Mermaid diagram (expand to render)
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Amyotrophic Lateral Sclerosis](/diseases/als)
- [Huntington's Disease](/diseases/huntingtons-disease)
- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-neurodegeneration)
- [Mitophagy](/mechanisms/mitophagy)
- [Mitochondrial Fusion in Neurodegeneration](/mechanisms/mitochondrial-fusion-neurodegeneration)
- [Mitochondrial Fission in Neurodegeneration](/mechanisms/mitochondrial-fission-neurodegeneration)
- [MFN1 Gene](/genes/mfn1)
- [MFN2 Gene](/genes/mfn2)
- [OPA1 Gene](/genes/opa1)
- [DRP1 Gene](/genes/drp1)
References
[Chan et al, Mitochondrial fusion and fission in neuronal function (2020)](https://doi.org/10.1016/j.neuroscience.2020.06.013)
[Chen et al, Mitochondrial dynamics in neurodegeneration (2023)](https://doi.org/10.1016/j.tcb.2023.01.001)
[Giacomello et al, Mitochondrial fission and fusion in cellular stress (2023)](https://doi.org/10.1038/s41580-023-00595-9)
[Liu et al, Mitofusin 2 in Alzheimer's disease (2022)](https://doi.org/10.1007/s12035-022-02889-1)
[Chen et al, Mitofusin-mediated mitochondrial fusion (2007)](https://doi.org/10.1073/pnas.0711441105)
[Zuchner et al, Mutations in the mitochondrial GTPase mitofusin 2 (2004)](https://doi.org/10.1056/NEJMoa040938)
[Liao et al, OPA1 mutations and optic atrophy (2021)](https://doi.org/10.1093/brain/awab445)
[Song et al, Drp1 and mitochondrial fission (2022)](https://doi.org/10.1016/j.tcb.2022.08.003)
[Peng et al, Regulation of mitochondrial dynamics in neurodegeneration (2023)](https://doi.org/10.1007/s00401-023-02565-7)
[高铁梅 et al, Calcium regulation of mitochondrial fusion (2019)](https://doi.org/10.1016/j.cell.2019.04.015)
[Wang et al, AMPK regulates mitochondrial dynamics (2019)](https://doi.org/10.1038/s41467-019-12145-1)
[Wang et al, Mitochondrial dysfunction in Alzheimer's disease (2022)](https://doi.org/10.1016/j.nbd.2022.105689)
[Manczak et al, Mitochondria-targeted amyloid beta (2016)](https://doi.org/10.1093/hmg/ddv305)
[Kopeidou et al, Tau pathology and mitochondrial dysfunction (2022)](https://doi.org/10.1007/s00401-022-02445-6)
[Wang et al, Mitofusin1 and mitofusin2 in AD (2019)](https://doi.org/10.1016/j.nbd.2019.104703)
[Yang et al, Mitochondrial dynamics modulation as therapy (2023)](https://doi.org/10.1038/s41582-023-00817-w)
[Park et al, Mitochondrial dynamics in Parkinson's disease (2023)](https://doi.org/10.1016/j.nbd.2023.105879)
[Narendra et al, Parkin induces mitochondrial autophagy (2008)](https://doi.org/10.1083/jcb.200809125)
[Poehler et al, Alpha-synuclein and mitochondrial dynamics (2014)](https://doi.org/10.1002/ana.24089)
[Rideout et al, LRRK2 and mitochondrial dysfunction (2016)](https://doi.org/10.1093/brain/aww067)
[Xie et al, Mitofusin2 in Parkinson's disease models (2019)](https://doi.org/10.1038/s41598-019-48123-2)
[Shi et al, Mitochondrial dysfunction in ALS (2020)](https://doi.org/10.1016/j.neurobiolaging.2020.06.014)
[Liu et al, SOD1 mutations and mitochondrial dynamics (2020)](https://doi.org/10.1016/j.jmb.2020.03.012)
[Lopez-Gonzalez et al, C9orf72 and mitochondrial dysfunction (2019)](https://doi.org/10.1093/brain/awz337)
[Wang et al, TDP-43 and mitochondrial dynamics (2018)](https://doi.org/10.1038/s41593-018-0268-0)
[Deng et al, FUS and mitochondrial dysfunction in ALS (2015)](https://doi.org/10.1093/brain/awv115)
[Costa et al, Mutant huntingtin and mitochondrial dynamics (2020)](https://doi.org/10.1093/brain/awaa011)
[Shirendeb et al, Mutant huntingtin interactions with mitochondrial proteins (2009)](https://doi.org/10.1074/jbc.M109.018564)
[Quintanilla et al, Mitochondrial bioenergetic deficits in HD (2013)](https://doi.org/10.1093/brain/awt056)
[Rascovsky et al, TDP-43 pathology in FTD (2019)](https://doi.org/10.1093/brain/awz330)
[Stefanova et al, Mitochondrial dysfunction in MSA (2019)](https://doi.org/10.1002/mds.27483)
[Zhang et al, Gene therapy for mitochondrial dynamics (2023)](https://doi.org/10.1038/s41587-023-01845-5)